[Federal Register Volume 81, Number 107 (Friday, June 3, 2016)]
[Notices]
[Page 35787]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-13112]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing and/or co-development in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing and/or co-development.

ADDRESSES: Invention Development and Marketing Unit, Technology 
Transfer Center, National Cancer Institute, 9609 Medical Center Drive, 
Mail Stop 9702, Rockville, MD 20850-9702.

FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent 
applications listed below, may be obtained by contacting: Attn. 
Invention Development and Marketing Unit, Technology Transfer Center, 
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, 
Rockville, MD 20850-9702, Tel. 240-276-5515 or email 
[email protected]. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
    Title of invention: Chimeric Antigen Receptors to CD276 for 
treating Cancer.
    Description of Technology: Chimeric antigen receptors (CARs) are 
hybrid proteins consisting of an antibody binding fragment fused to 
protein signaling domains that cause T-cells which express the CAR to 
become cytotoxic. Once activated, these cytotoxic T-cells can 
selectively eliminate the cells which they recognize via the antibody 
binding fragment of the CAR. By engineering a T-cell to express a CAR 
that is specific for a certain cell surface protein, it is possible to 
selectively target those cells for destruction. This is a promising new 
therapeutic approach known as adoptive cell therapy.
    CD276 (a.k.a., B7-H3) is a tumor-associated antigen that is 
expressed on the cell surface of several cancers, including 
neuroblastomas, prostate cancer, ovarian cancer and some lung cancers. 
This technology concerns the development of CARs comprising an antigen-
binding fragment derived from the MGA271 antibody. The resulting CARs 
can be used in adoptive cell therapy treatment for neuroblastoma and 
other tumors which express CD276.
    Potential Commercial Applications:
     Treatment of cancers associated with expression of CD276.
     Specific cancers include neuroblastoma, prostate cancer, 
ovarian cancer, lung cancer and other solid tumors.
    Value Proposition:
     MGA271 is a well characterized anti-CD276 antibody, making 
it a known quantity regarding safety issues.
     High affinity of the MGA271 antibody for CD276 increases 
the likelihood of successful targeting.
     Targeted therapy decreases non-specific killing of 
healthy, essential cells, resulting in fewer non-specific side-effects 
and healthier patients.
    Development Stage: Discovery (Lead ID).
    Inventor(s): Crystal Mackall.
    Intellectual Property: HHS No. E-243-2015/0-US-01 U.S. Provisional 
Application 62/216,447 (E-243-2015/0-US-01) filed 9/10/2015 titled 
``Anti-CD276 Chimeric Antigen Receptors''.
    Publications: None applicable.
    Collaboration Opportunity: Researchers at the NCI seek licensing 
for chimeric antigen receptors to CD276 for treating cancer.
    Contact Information: Requests for copies of the patent application 
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D., 
email: [email protected].

    Dated: May 31, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National 
Cancer Institute.
[FR Doc. 2016-13112 Filed 6-2-16; 8:45 am]
 BILLING CODE 4140-01-P